Merck says it has agreed to supply potential COVID-19 drug Rebif to EU countries
German drugmaker Merck said on Wednesday it had agreed to supply its potential COVID-19 drug Rebif to European Union countries should orders be placed for the treatment. The comment followed a Reuters report earlier on Wednesday about a deal reached by the EU Commission and Merck for the supply of Rebif.
- Country:
- Germany
German drugmaker Merck said on Wednesday it had agreed to supply its potential COVID-19 drug Rebif to European Union countries should orders be placed for the treatment. The comment followed a Reuters report earlier on Wednesday about a deal reached by the EU Commission and Merck for the supply of Rebif. A similar deal was struck with Roche about possible COVID-19 treatment RoActemra.
"Merck has been asked by the European Commission to be prepared to supply one of its medicines, Rebif (Interferon beta-1a), to EU countries upon request if and when the indication for COVID-19 treatment is adjudicated," the company said in a statement to Reuters. Rebif is currently used for the treatment of relapsing multiple sclerosis and is being tested as a possible therapy for COVID-19 patients.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Merck
- European Union
- COVID
- EU Commission
- Roche
- COVID-19
ALSO READ
My taxable income plummeted to Rs 680 in 2021-22 due to Covid-19 losses: BJP's Chandrasekhar
MSMEs in TN crushed by triple impact of demonetisation, GST, and unplanned COVID lockdowns: Congress
Health News Roundup: Sanofi to overhaul US operations of vaccines, cut jobs; After COVID, WHO defines disease spread 'through air' and more
European Union Investigates TikTok's New App That Rewards Users for Watching Videos
European Union official urges G7 to step up air defence for Ukraine and expand Iran sanctions